<table cellpadding="0pt" cellspacing="0pt" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<col width="33%"></col>
<col width="33%"></col>
<col width="33%"></col>
<tbody>
<tr>
<td align="center" colspan="3" stylecode="Rrule Botrule Lrule Toprule " valign="top">
<paragraph>
<content stylecode="bold">Drugs That are Affected by Ciprofloxacin </content>
<br/>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="bold">Drug(s)</content>
<br/>
</paragraph>
</td>
<td align="center" stylecode="Rrule Botrule " valign="top">
<paragraph>
<content stylecode="bold">Recommendation</content>
<br/>
</paragraph>
</td>
<td align="center" stylecode="Rrule Botrule " valign="top">
<paragraph>
<content stylecode="bold">Comments</content>
<br/>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Tizanidine<br/>
</paragraph>
</td>
<td align="center" stylecode="Rrule Botrule " valign="top">
<paragraph>Contraindicated<br/>
</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>Concomitant administration of tizanidine and ciprofloxacin  is contraindicated due to the potentiation of hypotensive and sedative effects of tizanidine <content stylecode="italics">[see <linkhtml href="#Section_4.2">Contraindications (4.2)</linkhtml>].</content>
<br/>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Theophylline<br/>
</paragraph>
</td>
<td align="center" stylecode="Rrule Botrule " valign="top">
<paragraph>Avoid Use (Plasma Exposure Likely to be Increased and Prolonged)<br/>
</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>Concurrent administration of ciprofloxacin with theophylline may result in increased risk of a patient developing central nervous system (CNS) or other adverse reactions. If concomitant use cannot be avoided, monitor serum levels of theophylline and adjust dosage as appropriate <content stylecode="italics">[see <linkhtml href="#Section_5.9">Warnings and Precautions (5.9)</linkhtml>].</content>
<br/>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Drugs Known to Prolong QT Interval<br/>
</paragraph>
</td>
<td align="center" stylecode="Rrule Botrule " valign="top">
<paragraph>Avoid Use<br/> <br/>
</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>Ciprofloxacin may further prolong the QT interval in patients receiving drugs known to prolong the QT interval (for example, class IA or III antiarrhythmics, tricyclic antidepressants, macrolides, antipsychotics) <content stylecode="italics">[see <linkhtml href="#Section_5.11">Warnings and Precautions (5.11)</linkhtml> and <linkhtml href="#Section_8.5">Use in Specific Populations (8.5)</linkhtml>].</content>
<br/>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Oral antidiabetic drugs<br/>
</paragraph>
</td>
<td align="center" stylecode="Rrule Botrule " valign="top">
<paragraph>Use with caution Glucose-lowering effect potentiated<br/>
</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>Hypoglycemia sometimes severe has been reported when ciprofloxacin and oral antidiabetic agents, mainly sulfonylureas (for example, glyburide, glimepiride), were co-administered, presumably by intensifying the action of the oral antidiabetic agent. Fatalities have been reported<content stylecode="italics">. </content>Monitor blood glucose when ciprofloxacin is co-administered with oral antidiabetic drugs <content stylecode="italics">[see <linkhtml href="#Section_6.1">Adverse Reactions (6.1)</linkhtml>].</content>
<br/>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Phenytoin<br/>
</paragraph>
</td>
<td align="center" stylecode="Rrule Botrule " valign="top">
<paragraph>Use with caution Altered serum levels of phenytoin <br/>(increased and decreased) <br/> <br/>
</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>To avoid the loss of seizure control associated with decreased phenytoin levels and to prevent phenytoin overdose-related adverse reactions upon ciprofloxacin discontinuation in patients receiving both agents, monitor phenytoin therapy, including phenytoin serum concentration during and shortly after co-administration of ciprofloxacin with phenytoin.<br/>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Cyclosporine<br/>
</paragraph>
</td>
<td align="center" stylecode="Rrule Botrule " valign="top">
<paragraph>Use with caution (transient elevations in serum creatinine)<br/>
</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>Monitor renal function (in particular serum creatinine) when ciprofloxacin is co-administered with cyclosporine.<br/>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Anti-coagulant drugs<br/>
</paragraph>
</td>
<td align="center" stylecode="Rrule Botrule " valign="top">
<paragraph>Use with caution (Increase in anticoagulant effect)<br/>
</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>The risk may vary with the underlying infection, age and general status of the patient so that the contribution of ciprofloxacin to the increase in INR (international normalized ratio) is difficult to assess. Monitor prothrombin time and INR frequently during and shortly after co-administration of ciprofloxacin with an oral anti-coagulant (for example, warfarin).<br/>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Methotrexate<br/>
</paragraph>
</td>
<td align="center" stylecode="Rrule Botrule " valign="top">
<paragraph>Use with caution Inhibition of methotrexate renal tubular transport potentially leading to increased methotrexate plasma levels<br/>
</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>Potential increase in the risk of methotrexate associated toxic reactions. Therefore, carefully monitor patients under methotrexate therapy when concomitant ciprofloxacin therapy is indicated.<br/>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Ropinirole<br/>
</paragraph>
</td>
<td align="center" stylecode="Rrule Botrule " valign="top">
<paragraph>Use with caution<br/>
</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>Monitoring for ropinirole-related adverse reactions and appropriate dose adjustment of ropinirole is recommended during and shortly after co-administration with ciprofloxacin <content stylecode="italics">[see <linkhtml href="#Section_5.16">Warnings and Precautions (5.16)</linkhtml>].</content>
<br/>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Clozapine<br/>
</paragraph>
</td>
<td align="center" stylecode="Rrule Botrule " valign="top">
<paragraph>Use with caution<br/>
</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>Careful monitoring of clozapine associated adverse reactions and appropriate adjustment of clozapine dosage during and shortly after co-administration with ciprofloxacin are advised.<br/>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>NSAIDs<br/>
</paragraph>
</td>
<td align="center" stylecode="Rrule Botrule " valign="top">
<paragraph>Use with caution<br/>
</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>Non-steroidal anti-inflammatory drugs (but not acetyl salicylic acid) in combination of very high doses of quinolones have been shown to provoke convulsions in pre-clinical studies and in postmarketing.<br/>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Sildenafil<br/>
</paragraph>
</td>
<td align="center" stylecode="Rrule Botrule " valign="top">
<paragraph>Use with caution Two-fold increase in exposure<br/>
</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>Monitor for sildenafil toxicity <content stylecode="italics">[see <linkhtml href="#Section_12.3">Clinical Pharmacology (12.3)</linkhtml>].</content>
<br/>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Duloxetine<br/>
</paragraph>
</td>
<td align="center" stylecode="Rrule Botrule " valign="top">
<paragraph>Avoid Use<br/>Five-fold increase in duloxetine exposure<br/>
</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>If unavoidable, monitor for duloxetine toxicity<br/>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Caffeine/Xanthine Derivatives<br/>
</paragraph>
</td>
<td align="center" stylecode="Rrule Botrule " valign="top">
<paragraph>Use with caution Reduced clearance resulting in elevated levels and prolongation<br/>of serum half-life<br/>
</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>Ciprofloxacin inhibits the formation of paraxanthine after caffeine administration (or pentoxifylline containing products). Monitor for xanthine toxicity and adjust dose as necessary.<br/>
</paragraph>
</td>
</tr>
<tr>
<td align="center" colspan="3" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="bold">Drug(s) Affecting Pharmacokinetics of Ciprofloxacin </content>
<br/>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Antacids, Sucralfate, Multivitamins and Other Products Containing Multivalent Cations (magnesium/aluminum antacids; polymeric phosphate binders (for example, sevelamer, lanthanum carbonate); sucralfate; Videx<sup>® </sup>(didanosine) chewable/ buffered tablets or pediatric powder; other highly buffered drugs; or products containing calcium, iron, or zinc and dairy products)<br/>
</paragraph>
</td>
<td align="center" stylecode="Rrule Botrule " valign="top">
<paragraph>Ciprofloxacin should be taken at least two hours before or six hours after Multivalent cation-containing products administration <content stylecode="italics">[see <linkhtml href="#Section_2.4">Dosage and Administration (2.4)</linkhtml>].</content>
<br/>
</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>Decrease ciprofloxacin absorption, resulting in lower serum and urine levels<br/>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Botrule Lrule " valign="top">
<paragraph>Probenecid<br/>
</paragraph>
</td>
<td align="center" stylecode="Rrule Botrule " valign="top">
<paragraph>Use with caution (interferes with renal tubular secretion of ciprofloxacin and increases ciprofloxacin serum levels)<br/>
</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>Potentiation of ciprofloxacin toxicity may occur.<br/>
</paragraph>
</td>
</tr>
</tbody>
</table>